NEW YORK (GenomeWeb News) – CollabRx, a San Francisco-based personalized cancer research services firm, today said that it has initiated a cancer sequencing project in collaboration with Alacris Pharmaceuticals.

The company said that the firms will work together on the TREAT 1000 project, which will sequence 1,000 genomes of people with cancer. It said that the project will "create a compendium of cancer genome information that will inform future research and treatment."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.